Charles Schwab Investment Management Inc. Has $7.33 Million Position in Sanofi (NASDAQ:SNY)

Charles Schwab Investment Management Inc. raised its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 8.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 151,945 shares of the company's stock after purchasing an additional 12,440 shares during the period. Charles Schwab Investment Management Inc.'s holdings in Sanofi were worth $7,328,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Victory Capital Management Inc. grew its stake in shares of Sanofi by 27.6% during the third quarter. Victory Capital Management Inc. now owns 8,669 shares of the company's stock worth $500,000 after purchasing an additional 1,876 shares during the period. Prospera Financial Services Inc increased its stake in shares of Sanofi by 5.6% in the 3rd quarter. Prospera Financial Services Inc now owns 11,432 shares of the company's stock valued at $659,000 after acquiring an additional 604 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Sanofi by 4.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 147,955 shares of the company's stock valued at $8,527,000 after acquiring an additional 6,796 shares during the period. Eagle Asset Management Inc. boosted its stake in Sanofi by 11.1% during the 3rd quarter. Eagle Asset Management Inc. now owns 6,582 shares of the company's stock worth $379,000 after acquiring an additional 658 shares during the last quarter. Finally, Citigroup Inc. boosted its stake in Sanofi by 2.5% during the 3rd quarter. Citigroup Inc. now owns 631,672 shares of the company's stock worth $36,403,000 after acquiring an additional 15,348 shares during the last quarter. Institutional investors own 14.04% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several research firms have weighed in on SNY. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. StockNews.com downgraded Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Sanofi has an average rating of "Moderate Buy" and an average price target of $62.50.

Sanofi Price Performance

Shares of SNY stock traded up $0.41 during trading hours on Thursday, reaching $54.91. The company's stock had a trading volume of 1,320,100 shares, compared to its average volume of 2,263,577. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12. The firm's 50 day simple moving average is $54.94 and its 200-day simple moving average is $52.83. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $139.35 billion, a price-to-earnings ratio of 22.05, a PEG ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Sell-side analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.